Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: Dyne Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco NS Pharma PepGen Pfizer Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
January 3, 2024

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

Dyne announces positive initial clinical data from its ACHIEVE trial of DYNE-101.
Read More
October 30, 2023

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

Dyne Therapeutics reports financial results for the third quarter of 2023 and more.
Read More
March 23, 2023

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne
Read More
November 7, 2022

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne Therapeutics receives FDA Fast Track designation for DYNE-251 for treatment of Duchenne
Read More
August 11, 2022

Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

On August 10, 2022, Dyne Therapeutics announced the publication of Duchenne muscular dystrophy preclinical data: Enhanced Exon Skipping and Prolonged Dystrophin Restoration Achieved by TfR1-Targeted Delivery of Antisense Oligonucleotide Using...
Read More
July 5, 2022

Dyne Therapeutics Announces FDA Lifts Clinical Hold for DYNE-251

On July 5, 2022, Dyne Therapeutics announced that the U.S. Food and Drug Administration lifted the hold and cleared their Investigational New Drug application for DYNE-251.
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Register Now

    Experience the magic this summer!

    Apply Today

    How is the rare disease community accomplishing goals?

    Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

    Register Today

    Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

    Give Today

    Accessible Vehicle Fund Applications Open

    Apply Today